Anticancer agent 195

Cat. No.: HY-158005

Molecular Formula: $C_{24}H_{28}O_6$

Molecular Weight: 412.48

Target: Apoptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Anticancer agent 195 (Compound 10) is an inhibitor for ELF3-MED23 PPI with K_i of 0.68 μM. Anticancer agent 195 induces apoptosis and exhibits antitumor activity[1].

IC_{50} & Target

>K_i: 0.68 μM (ELF3-MED23 PPI)

In Vitro

Anticancer agent 195 (10 μM) blocks the ELF3-MED23 interaction, inhibits activity of HER2 promoter and followed phosphorylation of AKT and MAPK[1].

Anticancer agent 195 (10 μM) reveals an anti-proliferative and apoptotic-inducing efficacy in cells NCI-N87, exhibits potency against trastuzumab resistance[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	NCI-N87, NCI-N87 TR
Concentration:	0-10 μM
Incubation Time:	16 h
Result:	Reduced levels of HER2, phosphorylated AKT and p-MAPK. Increased cleaved PARP and c-caspase 3.

Apoptosis Analysis[1]

Cell Line:	NCI-N87, NCI-N87 TR
Concentration:	0-15 μM
Incubation Time:	24 h
Result:	Induced apoptosis in a dose-dependent manner.

In Vivo

Anticancer agent 195 (4 mg/kg, i.v. for 25 days) inhibited tumor growth in NCI-N87 xenograft athymic nude mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCI-N87 xenograft athymic nude mice[1]
Dosage:	4 mg/kg
Administration:	i.v., every three days for 25 days
Result:	Inhibited tumor growth.

REFERENCES

[1]. Hwang SY, et al., Synthesis and Biological Assessment of Chalcone and Pyrazoline Derivatives as Novel Inhibitor for ELF3-MED23 Interaction, Cold Spring Harbor Laboratory, 2024

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA